Acute Effects of Rhodiola Rosea and Caffeine on Mean Propulsive Velocity Loss in Resistance Training (Rhocaf2)
The Acute Effects of 1,000 mg of Rhodiola Rosea and 3 mg/kg of Caffeine on Mean Propulsive Velocity Loss in Advanced Resistance-Trained Subjects: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial
The goal of this clinical trial is to evaluate if combined acute supplementation with Rhodiola rosea and caffeine is superior to single-ingredient intake or placebo in attenuating neuromuscular fatigue in advanced resistance-trained subjects.
The main questions it aims to answer are:
Does combined supplementation attenuate mean propulsive velocity loss during heavy resistance exercise? Does combined supplementation reduce ratings of perceived exertion and increase repetitions performed to failure?
Researchers will compare four experimental conditions (placebo, caffeine alone, Rhodiola rosea alone, and combined supplementation) in a randomized crossover design to see if co-ingestion provides superior anti-fatigue benefits.
Participants will:
Complete a familiarization session to establish individual strength baselines. Attend 4 testing visits separated by a 72-hour washout period. Ingest the assigned treatment before testing. Perform a back squat fatigue protocol (3 sets at 70% 1RM) and complete perceptual evaluations.The goal of this clinical trial is to evaluate if combined acute supplementation with Rhodiola rosea and caffeine is superior to single-ingredient intake or placebo in attenuating neuromuscular fatigue in advanced resistance-trained subjects.
The main questions it aims to answer are:
Does combined supplementation attenuate mean propulsive velocity loss during heavy resistance exercise? Does combined supplementation reduce ratings of perceived exertion and increase repetitions performed to failure?
Researchers will compare four experimental conditions (placebo, caffeine alone, Rhodiola rosea alone, and combined supplementation) in a randomized crossover design to see if co-ingestion provides superior anti-fatigue benefits.
Participants will:
Complete a familiarization session to establish individual strength baselines. Attend 4 testing visits separated by a 72-hour washout period. Ingest the assigned treatment before testing. Perform a back squat fatigue protocol (3 sets at 70% 1RM) and complete perceptual evaluations.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This study is a randomized, double-blind, placebo-controlled, four-arm crossover trial designed to investigate the acute neuromuscular and ergogenic effects of single and combined supplementation with Rhodiola rosea (1,000 mg) and caffeine (3 mg/kg) in advanced resistance-trained subjects.
Neuromuscular fatigue during heavy resistance training impairs movement velocity, power output, and overall volume performance. While caffeine is a central nervous system stimulant that enhances motor unit recruitment and reduces perceived exertion, Rhodiola rosea is an adaptogen proposed to modulate central monoamines and attenuate fatigue during high-intensity effort. This protocol evaluates whether co-ingestion provides a synergistic advantage over isolated administration or placebo in maintaining movement execution quality and accelerating acute recovery.
Study Procedures:
Familiarization Session: Prior to the experimental trials, participants complete a familiarization session to establish baseline measurements and estimate 1-repetition maximum (1RM) in the barbell back squat using a two-point load-velocity method (using loads corresponding to ~1.0 m/s and ~0.5 m/s) with a linear position transducer.
Experimental Trials (4 Visits): Participants complete four experimental testing visits in a randomized, counterbalanced order, separated by a 72-hour washout period.
During each of the 4 experimental visits, participants complete the following sequence:
Supplement Ingestion: Double-blind administration of the assigned treatment:
Rhodiola placebo consists of opaque cornstarch capsules. Caffeine placebo consists of a 60 mL liquid solution containing sweetener, 3 g of sugar, and 1 g of citric acid.
Active conditions consist of 1,000 mg of Rhodiola rosea and/or 3 mg/kg of caffeine.
Pre-Exercise Evaluation: Completion of baseline perceptual questionnaires. Velocity Determination: Identification of the exact load corresponding to a Mean Propulsive Velocity (MPV) of 1.0 ± 0.03 m/s in the back squat.
Acute Fatigue Protocol: Execution of 3 sets at 70% estimated 1RM in the back squat performed to muscular failure, recording total repetitions and velocity loss across sets.
Post-Fatigue Velocity Recovery: Re-assessment of MPV using the pre-determined 1.0 m/s load at exactly 1 minute and 2 minutes post-fatigue protocol to evaluate acute neuromuscular fatigue and velocity recovery.
Perceptual Evaluation: Rating of Perceived Exertion (RPE) recorded post-exercise.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: David Gomez Castillo, PhD Candidate
- Numéro de téléphone: +52 2382091643
- E-mail: david.gomezcs@uanl.edu.mx
Sauvegarde des contacts de l'étude
- Nom: Marina Medina Corrales, PhD
- Numéro de téléphone: +52 8115358121
- E-mail: marina.medinacr@uanl.edu.mx
Lieux d'étude
-
-
Nuevo León
-
San Nicolás, Nuevo León, Mexique, 66455
- Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
-
Contact:
- Marina Medina Corrales, PhD
- Numéro de téléphone: +528115358121
- E-mail: marina.medinacr@uanl.edu.mx
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Healthy males and females.
- Advanced resistance training experience (as defined by Santos et al., 2021): 1 to 3 years of consistent resistance training experience, demonstrating proper barbell back squat technique.
- Relative maximum strength (estimated 1RM back squat): Minimum of 150% of body mass for men, and 130% of body mass for women.
- Habitual caffeine consumers (e.g., daily intake via coffee, tea, sports gels, or energy drinks).
- Commitment to maintaining current nutritional habits and training routines throughout the study period.
- Ensured stable consumption of dietary supplements with cumulative effects (e.g., creatine, beta-alanine, nitrates, citrulline, betaine) for at least one month prior to and throughout the experimental protocol, with a commitment to not alter the dosage. Intake will be recorded and standardized.
- Availability to attend all scheduled evaluations.
- Provision of written informed consent validating full understanding of the study protocols.
Exclusion Criteria:
- Presence of cardiovascular diseases (e.g., arterial hypertension, arrhythmias) or metabolic disorders (e.g., type 1 or type 2 diabetes mellitus).
- At least one affirmative response on the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+).
- History of anabolic steroid use (less than 4 years) or use of World Anti-Doping Agency (WADA) prohibited performance-enhancing substances.
- Consumption of supplements with acute ergogenic effects (e.g., coffee, energy drinks, pre-workout supplements) within 12 hours prior to testing sessions, or failure to comply with a minimum 4-hour fasting period prior to the experimental session. (Note: Subjects violating these criteria will have their session rescheduled).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
Placebo condition consisting of opaque cornstarch capsules and a 60 mL placebo liquid solution. |
Opaque cornstarch capsules matching the active Rhodiola capsules. 60 mL liquid solution containing sweetener, 3 g of sugar, and 1 g of citric acid. |
|
Expérimental: Caffeine
Single administration of caffeine alongside placebo capsules. |
Opaque cornstarch capsules matching the active Rhodiola capsules. 3 mg/kg of caffeine administered in a 60 mL liquid solution. |
|
Expérimental: Rhodiola rosea
Single administration of Rhodiola rosea alongside placebo liquid solution. |
60 mL liquid solution containing sweetener, 3 g of sugar, and 1 g of citric acid. 1,000 mg of Rhodiola rosea administered in opaque capsules. |
|
Expérimental: Rhodiola rosea + Caffeine
Combined administration of Rhodiola rosea and caffeine. |
3 mg/kg of caffeine administered in a 60 mL liquid solution. 1,000 mg of Rhodiola rosea administered in opaque capsules. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage Loss in Mean Propulsive Velocity (MPV)
Délai: Baseline (pre-fatigue), 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks.
|
Percentage loss in mean propulsive velocity (MPV) following the fatiguing protocol. MPV is assessed during the barbell back squat using an individualized load corresponding to an initial velocity of 1.0 ± 0.03 m/s, recorded via a linear position transducer. Percentage loss is calculated relative to pre-fatigue baseline as: [(baseline MPV - post-fatigue MPV) / baseline MPV] × 100. The fatiguing protocol consists of 3 sets to failure at 70% 1RM. |
Baseline (pre-fatigue), 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total Number of Repetitions to Failure
Délai: Immediately upon completion of the fatiguing exercise protocol, up to 2 weeks
|
Cumulative number of successful repetitions completed across 3 sets at 70% 1RM performed to momentary muscular failure during the fatiguing protocol. Data are reported as the total number of repetitions completed per experimental condition. |
Immediately upon completion of the fatiguing exercise protocol, up to 2 weeks
|
|
Rating of Perceived Exertion (RPE)
Délai: Immediately, 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks
|
Subjective perception of effort assessed using a standardized RPE scale immediately following the fatiguing protocol to quantify internal load. |
Immediately, 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: José Raúl Hoyos Flores, PhD, Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
- Directeur d'études: Marina Medina Corrales, PhD, Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
- Chaise d'étude: Myriam Zaraí García Dávila, PhD, Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CEIFOD 0125028
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Délai de partage IPD
Data will become available after publication of the main manuscript in a peer-reviewed journal and will remain accessible indefinitely.
Critères d'accès au partage IPD
Data and supporting materials will be publicly accessible via the Open Science Framework (OSF) repository to any researcher interested in secondary or meta-analysis.
Type d'informations de prise en charge du partage d'IPD
- CIF
- ANALYTIC_CODE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .